The DEA has not finalized rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act, despite President Trump's December 2025 executive order directing completion in the "most expeditious manner" after HHS's 2023 scientific recommendation recognizing medical uses. Momentum persists with Rep. Steve Cohen's March 27 letter demanding an update from AG Pam Bondi and DEA Administrator Terry Cole, amid reports of Bondi's firing and Trump's consideration of Alina Habba—who backs regulated, contaminant-free cannabis but opposes recreational use—as replacement, potentially influencing DOJ oversight. No firm rulemaking timeline exists, but congressional pressure and leadership shifts could accelerate or delay action before mid-2026 deadlines in related prediction markets.
Polymarketデータを参照したAI生成の実験的な要約 · 更新日$285,995 Vol.
2026/03/31
6月30日
13%
12月31日
43%
$285,995 Vol.
6月30日
$11,142 Vol.
13%
12月31日
$9,970 Vol.
43%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA has not finalized rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act, despite President Trump's December 2025 executive order directing completion in the "most expeditious manner" after HHS's 2023 scientific recommendation recognizing medical uses. Momentum persists with Rep. Steve Cohen's March 27 letter demanding an update from AG Pam Bondi and DEA Administrator Terry Cole, amid reports of Bondi's firing and Trump's consideration of Alina Habba—who backs regulated, contaminant-free cannabis but opposes recreational use—as replacement, potentially influencing DOJ oversight. No firm rulemaking timeline exists, but congressional pressure and leadership shifts could accelerate or delay action before mid-2026 deadlines in related prediction markets.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
マーケット開始日： Feb 7, 2026, 5:04 PM ET
音量
$285,995終了日
2026/03/31マーケット開始日
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA has not finalized rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act, despite President Trump's December 2025 executive order directing completion in the "most expeditious manner" after HHS's 2023 scientific recommendation recognizing medical uses. Momentum persists with Rep. Steve Cohen's March 27 letter demanding an update from AG Pam Bondi and DEA Administrator Terry Cole, amid reports of Bondi's firing and Trump's consideration of Alina Habba—who backs regulated, contaminant-free cannabis but opposes recreational use—as replacement, potentially influencing DOJ oversight. No firm rulemaking timeline exists, but congressional pressure and leadership shifts could accelerate or delay action before mid-2026 deadlines in related prediction markets.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
音量
$285,995終了日
2026/03/31マーケット開始日
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The DEA has not finalized rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act, despite President Trump's December 2025 executive order directing completion in the "most expeditious manner" after HHS's 2023 scientific recommendation recognizing medical uses. Momentum persists with Rep. Steve Cohen's March 27 letter demanding an update from AG Pam Bondi and DEA Administrator Terry Cole, amid reports of Bondi's firing and Trump's consideration of Alina Habba—who backs regulated, contaminant-free cannabis but opposes recreational use—as replacement, potentially influencing DOJ oversight. No firm rulemaking timeline exists, but congressional pressure and leadership shifts could accelerate or delay action before mid-2026 deadlines in related prediction markets.
Polymarketデータを参照したAI生成の実験的な要約 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問